Skip to main content
. Author manuscript; available in PMC: 2024 Sep 9.
Published in final edited form as: Vaccine. 2020 Feb 20;38(14):3042–3049. doi: 10.1016/j.vaccine.2020.02.035

Figure 4.

Figure 4.

Correlation between increased amino acid substitutions in NAg1 and decreasing median neutralization titers for highly divergent type 2 iVDPVs. A substitution matrix based on the JTT model was used to compare amino acid residues mapped to (A) NAg1, (B) NAg2, (C) NAg3a, and (D) NAg3b.